Aprovel 300 mg papa Helu 28

Lapaʻau lāʻau

ʻO ka ʻāneʻa ala ala Angiotensin II. E kumu ai kahi hoʻonui renina angiotensin II i ke koko a me ka emi ʻana o ka neʻe ʻana aldosterone. ^ E Ha yM. Nā kikowaena pākaukauʻaʻole e hoʻololi ka koko.
Hoʻololi ka hopena-Dose i ke kahe o ke koko, akā ke noi ʻia ma luna o 900 mg / lā, hiki ke hoʻopau ʻia ka piʻi ʻana o ka hopena hypotensive. Hōʻike ka emi ʻana o ke koko ma hope o nā hola 3-6, e hoʻomau ka hopena no 24 mau hola.
ʻO ka hopena antihypertensive ulu ka 1-2 pule, a ua ʻike ʻia ka nui o ka wā ma hope o 1-1,5 mau mahina. ʻAʻole hilinaʻi ka pono i ka male. ʻAʻole pili ka lāʻau lapaʻau i ke kiʻekiʻe o ka uric acid i ke koko. ʻAʻole mālama ʻia ka maʻi kāpae.

ʻAʻole pili ʻo Irbesartan i ka hana papala i ka poʻe maʻi me maʻi nephropathy maʻi, glomerulonephritisno laila, ʻo ka lāʻau lapaʻau ke koho ma kēia mau maʻi.

Lapaʻau lāʻau

Hoʻonohonoho maikaʻi ia, bioavailability o 60-80%. Hoʻoholo ʻia ka manaʻo kiʻekiʻe loa i ke koko ma hope o nā hola 1,5-2, ʻo ka mea kaulike - ma hope o 3 mau lā. Hoʻopaʻa ʻia ia i nā protein i ka 96%.

Hoʻomili ʻia ia e ka ʻōnaehana cytochrome P450 CYP2C9. Ke hoʻohālikelike ʻia nei ia i nā pōpoki a me nā pōpoki. ʻO T1 / 2 he mau hola 11-14. No ka mea maʻi me ka hana hoʻopalapula o kēia mau kino, me ka poʻe no nā kānaka kahiko, ʻaʻole i hoʻokomo ʻia ka hoʻoponopono hoʻoponopono ʻia.

Nā hōʻailona no ka hoʻohana ʻana

Hoʻohana ʻia ʻo Aprovel no:

Ma ka akahele me ka hoʻomanaʻo ʻana hyponatremia, he stenosis aortic valve, stenosis hāmeʻa like ʻole, maʻi maʻi coronarykaumaha maʻiilaa nā mālamalama maikaʻi ʻole.

Nā hopena hopena

Ma muli o Aprovel:

• āhāhuʻe orthostatic hypotension,
• nāwaliwali
• tachycardia,
• huhū, ʻehaʻeha,
• paila, mamaila, nā niniapuʻuwai
• moekolohe,
• hoʻonui i CPK, hyperkalemia,
• nā iwi a me nā ʻehaʻeha
• ʻohi, urticaria, angioedema.

Nā ʻōkuhi no ka hoʻohana ʻana o Aprovel (Ke ʻano a me ka anaana)

Lawe ʻia ka papa papa me ka ʻaʻa ʻole ʻana. Hoʻomaka ka lāʻau lapaʻau me 150 mg hoʻokahi i ka lā, e hāʻawi kēia lāʻau ma ke kahe koko i 24 mau hola. Me ka hanaʻole, piʻi ka hopena i 300 mg.

I mellitus type II mellitus me ka maʻi hypertension Ua kuhikuhi mua ʻia ka 150 mg / lā me ka hoʻonui ʻana o ka piʻi a hiki i 300 mg, ʻoiai ʻoi aku ka makemake o kēia lāʻau i ka mālama ʻana nephropathy. ^ E Ha yM. No nā poʻe ma luna o ka 75 mau makahiki o a me nā mea maʻi ma ka hemodialysis, ua kuhikuhi ʻia ka lāʻau lapaʻau ma kahi mua o 75 mg. Hoʻohui ka koho ʻana o kahi diuretic i ka hopena o ka lāʻau.

Ka lāʻau Co. Aprovel ka hui pū ʻana o irbesartan + huinahui in dosages of 150 mg / 12.5 mg a 300 mg / 12.5 mg.

ʻO nā ʻōkuhi no ka hoʻohana ʻana ʻo Aprovel e loaʻa ai ka ʻike e pili ana i ka maʻi renal a me ka hana hepatic i nā mea maʻi ʻaʻole pono ia i ke hoʻoponopono hoʻoponopono.

Ke keu

Ke kiʻi nei i kahi kaʻe ma kahi o 900 mg / lā. no nā malama 2 ʻaʻole i mālama pū ʻia e nā maʻi overdose. Nā hōʻailona paha: brieociaiaa i ʻole tachycardiakaomi ʻana i ke koko.

Hoʻolālā ka hoʻomaʻamaʻa ʻana o ka gastage lavage, ka nānā ʻana o ka mea maʻi, a me ka mālama maʻi.

Hoʻohui

Aprovel i ka wā i hoʻohana ʻia me ka hoʻomākaukau pākia me nā mea e hiki ai ke hoʻonui i ka paʻakai ma ke koko. Nā diuretaha Thiazide hoʻoikaika i kona hopena hypotensive.

Mākaukau e pili ana aliskirenʻAʻole hiki ke hoʻohana pū me Aprovel i ka manawa maʻi maʻi a i ʻole nā mālamalama maikaʻi ʻole, no ka mea, aia he hopena nui o ka hoʻemi nui ʻana i ke koko, ke kīlohelohe ʻole o ka hana a me ka hiki i ka nui hyperkalemia.

I ka manawa e hoʻohana ai me nā lāʻau lapaʻau lithiumPaipai ʻia ka lithium koko.

Nā NSAIDhoʻonāwaliwali i ka hopena hypotensive, hoʻonui i ka nui o ka pāhana a me ka nui o ko ka pilikia o ka hana ʻole i ke kīpoki.

ʻAʻole pili ʻo Irbesartan i ka pharmacokinetics kāmakua.

Ke hana lāʻau lapaʻau e Aprovel

Wahi a nā ʻōlelo kuhikuhi, ua kōkua ʻo Aprovel i ka hōʻemi ʻana i ke koko me ka ʻole ka pā i ka puʻuwai aloha. 3-6 hola ma hope o ka lawe ʻana iā Aprovel, ua ʻike ʻia kahi emi nui o ke kaʻe o ke koko. Loaʻa ka hopena o ka lāʻau i kahi lā. Inā ʻoe e inu i kahi papa Aprovel ma kahi pona o 150 mg, a laila e like ka hopena therapeutic like me ka lawe ʻana i ka lāʻau lapaʻau 75 mg ʻelua. Wahi a nā ʻōlelo kuhikuhi, he hopena hypotensive ʻo Aprovel, e ulu nei i loko o hoʻokahi a i ʻelua pule mai ka hoʻomaka ʻana o ka lawe ʻana i ka lāʻau. Loaʻa ka hopena kiʻekiʻe loa e hoʻohana ai me Aprovel i nā hopena maikaʻi ma hope o nā mau hebedoma 4-6 mai ka hoʻomaka ʻana o ka lāʻau lapaʻau. ʻO nā loiloi e pili ana iā Aprovel i ka wā e hoʻōki ai ʻoe i ka lawe ʻana i ka lāʻau, hoʻomau ka hopena hypotensive no kekahi manawa hou aku. ʻAno e haʻalele ka lāʻau lapaʻau Aprovel. Hoʻokuʻu ʻia ʻo Aprovel mai ke kino me ka ʻili a me ka urine.

ʻO nā ʻano e hoʻokuʻu a me ka hoʻokumu ʻana o Aprovel

ʻO ka ʻoihana kūʻai lapaʻau e hana ia Aprovel i ke ʻano o nā papa o 150 mg a me 300 mg. Aia nā papa aprovel i kahi ʻano biconvex, ua ʻulaʻula, nā keʻokeʻo. ʻO ka papa kō he 14 mau papa. I kahi pahu kāleka o ka lāʻau lapaʻau, hoʻopauʻo Aprovel i hoʻokahi, ʻelua a ʻehā paha.

ʻO ka mea ikaika e ʻāpana o ka lāʻau i ka irbesartan.

Nā Hoʻohui

ʻO ka contraindication i ka hoʻohana ʻana o Aprovel he hypersensitivity i kekahi ʻāpana o ka lāʻau. E like me nā ʻōlelo aʻoaʻo, ʻaʻole pono e lawe ʻia ʻo Aprovel i ka wā hāpai a me ka lactation. Inā inā pono, ua faatonuina ka wahine i ka lāʻau lapaʻau Aprovel i ka wā o ka hoʻoulu ʻana, a laila i ka wā o ka mālama ʻana e pono ai e haʻalele i ka ʻokiʻoki. Me ka mālama aka, hoʻohana ʻia ʻo Aprovel i nā mea maʻi ma lalo o nā makahiki he 18, ʻoiai ʻo nā noi palekana e pili ana i ka hoʻomalu i ka lāʻau lapaʻau e kēia pūʻulu o nā maʻi ʻaʻole i lawe ʻia.

ʻLoe a me ke kākele

Wahi a nā ʻōlelo aʻo, ua lawe waha ʻia ʻo Aprovel. Inu i ka wai ʻole o ka ʻahaʻaina, hoʻokahi i ka lā. ʻO ka maʻa mua o Aprovel he 150 mg - inā pono, hiki iā ʻoe ke hoʻonui iā 300 mg o ka lāʻau i kēlā me kēia lā. I nā maʻi me ka hōʻeha o ka renal, ʻo ka nui o ka lāʻau ma mua o 75 mg i kēlā me kēia lā. Pono ka poʻe maʻi ma mua o 75 mau makahiki e lawe i kahi pualikua mua o Aprovel i ka nui o ka 75 mg. No ka mālamaʻana i nā mea maʻi me ka maʻi hypertension a me ke ʻano type 2, ʻo ka hopena mua o Aprovel ʻo 150 mg i kēlā me kēia lā. A laila hiki ke hoʻonui iki i ka 300 mg. Hōʻike nā loiloi o Aprovel i kahi hopena hypotensive maikaʻi i nā mea maʻi me ka hypertension koʻikoʻi.

Nā ʻōkuhi o Aprovel (APROVEL) no ka hoʻohana

mea waiwai: irbesartan, 1 papa o 75 mg he 75 mg o irbesartan, 1 papa o 150 mg he 150 mg o irbesartan, 1 papa o 300 mg he 300 mg o irbesartan,
nā mea hoʻowalewale: lactose, palaoa starch, croscarmellose sodium, poloxamer 188, hydrated silicon dioxide, microcrystalline cellulose, magnesium stearate.

ʻLoe a me ke kākele

ʻO ka pā mua a me ka mālama mālama ʻia he 150 mg hoʻokahi i kēlā me kēia lā me ka meaʻai a ma luna o ka ʻōpū ʻole. ʻO Aprovel i kahi maʻa o 150 mg hoʻokahi mau lā i ka lā e hāʻawi ai i kahi kahe 24 o ka maikaʻi o ke koko ma mua o kahi ma mua o ka 75 mg. Eia nō naʻe, ma ka hoʻomaka ʻana o nā hōʻola, hiki ke hoʻohana ʻia he ʻano lāʻau o 75 mg, ka mea kūikawā no nā mea maʻi ma ka hemodialysis, a i nā mea maʻi no nā makahiki he 75 a keu paha.

No nā maʻi nā kaʻai ʻole o ke koko ʻaʻole lawa i ka nui o ka wai ma kahi o ka 150 mg i hoʻokahi lā i ka lā, e hoʻonui ʻia ka nui o ka Aprovel i 300 mg hoʻokahi i ka lā a i ʻole e kuhikuhi ʻia ka lāʻau antihypertensive hou. No ka mea, ua hōʻike ʻia ka hoʻohui ʻia ʻana o kahi diuretic, e like me ka hydrochlorothiazide, i ka hopena me Aprovel e loaʻa ai ka hopena hou.

No nā mea maʻi me ka maʻi maʻi hypertension a me ka maʻi type 2, pono e hoʻomaka ʻia ka lāʻau ʻana me kahi maʻi o 150 mg o irbesartan hoʻokahi manawa i ka lā, a laila e lawe iā ia i ka 300 mg hoʻokahi manawa i ka lā, ʻo ia ka hopena maikaʻi loa e mālama ai i nā maʻi me ka maʻi o ka maʻi.

Ua hōʻike ʻia ka hopena nephroprotective maikaʻi loa o Aprovel i nā ʻōpū i loko o nā mea maʻi me ka maʻi hypertension a me ke ʻano type II no nā haʻawina kahi i hoʻohana ʻia ai ka irbesartan ma ke ʻano he hana hou i nā lāʻau antihypertensive, inā pono, e hoʻokō ai i ka pae kiʻekiʻe o ke koko.

ʻAʻole pono ia ʻo Renal i ka hoʻoponopono ʻana i ka maʻi no nā maʻi me ka hana renal impaired. No nā mea maʻi ma ka hemodialysis, pono e hoʻohana ʻia kahi pālākī mua (75 mg).

Hoʻolaha i BCC. ʻO ka nui o ke kahe a me ka hoʻoneʻe ʻana i ke koko a me / me ka liʻiliʻi o ka paʻakai, ua pono ia e hoʻoponopono ma mua o ka hoʻohana ʻana i ka lāʻau "Aprovel".

ʻO ka hana hema ʻole. No nā mea maʻi me ka maʻi hepatic palupalu, ʻaʻole pono. ʻAʻoheʻike loea ma ka hoʻohana ʻana i ka lāʻau lapaʻau i nā mea maʻi me ka maʻi hepatic koʻikoʻi.

ʻO nā maʻi maʻi. ʻOiai ke hoʻomaka nei ke mālama ʻana i nā poʻe maʻi ma mua o 75 mau makahiki he nui me ka nui o 75 mg, ʻaʻole pono ʻia ka hoʻoponopono ʻana.

Hoʻohana ma ka pediatrics. ʻAʻole ʻōlelo ʻia ʻo Irbesartan no ka mālama ʻana i nā keiki a me nā ʻōpio ma muli o ka ʻike ʻole o ka ʻike i kona palekana a me ka hiki.

Nā hopena maikaʻiʻole

ʻO ke ʻano o ka hana ʻino i hōʻike ʻia ma lalo nei: ua maʻamau loa (³1 / 10), maʻamau (³1 / 100, 2% nā mea maʻi ma mua o nā mea maʻi e loaʻa ana i ka placebo.

Mai ka pūnaehana pili ʻana. ʻO ka maʻi lahilahi maʻamau.

ʻO nā maʻi kikoʻī Nā hypotension maʻamau orthostatic.

ʻO nā maʻi o ka musculoskeletal, nā pilikia o ka hoʻopili ʻana a me nā iwi. ʻO ka ʻeha musculoskeletal maʻamau.

Pūnaewele noiʻi. ʻO ka Hyperkalemia e loaʻa hou i nā maʻi maʻi maʻi i loaʻa i ka irbesartan ma mua o ka placebo. I nā maʻi me ka maʻi maʻi me ka maʻi hypertension, he microalbuminuria a me ka hana maʻamau maʻamau, hyperkalemia (³ 5.5 mEq / mol) i nānā ma ka 29,4% (mau hopena ka hopena maʻamau) o nā mea maʻi e loaʻa he 300 mg o irbesartan a ma ka 22% o nā maʻi e loaʻa ana i ka placebo . ^ E Ha yM. I nā maʻi me ka maʻi maʻi me ka maʻi hypertension, ua loaʻa ka hopena ʻole o ka renal a me ka proteinuria koʻikoʻi, ʻo hyperkalemia (³ 5.5 mEq / mol) i nānā i ka 46.3% (ka hopena maʻamau loa) o nā mea maʻi e loaʻa ana i ka abbesartan a ma ka 26.3% o nā mea maʻi e loaʻa placebo.

ʻO ka emi ʻana o ka hemoglobin, ka mea ʻaʻole i koʻikoʻi ke kino, ua ʻike ʻia ma ka 1,7% (mau hopena maʻamau) nā maʻi maʻi hypertensive a me ka nephropathy maʻi holomua i mālama ʻia me irbesartan.

ʻO nā hopena ʻehā aʻe hou i hōʻike ʻia i ka wā noiʻi ma hope o ka noiʻi noiʻi. Ma muli o kēia ʻikepili i loaʻa mai i nā leka maʻamau, hiki ʻole ke hoʻoholo i ke alapine o kā lākou hanana.

Mai ka pānaʻi. E like me nā poʻe antagonist reseption angiotensin II, hōʻike kūlike ke ʻano hypersensitivity, e like me ka wikiwiki, urticaria, angioedema.

ʻO ka hanaʻinoʻole o nā hana o ka metabolism a me ka laweʻana o nā mea kanu. Hyperkalemia

Mai ka pūnaehana pili ʻana. Laumapa.

ʻO ka hoʻolohe ʻana i nā hana hōʻino a me nā mea hana vestibular. Tinnitus.

Nā maʻi Gastrointestinal. ʻO Dysgeusia (loli i ka ʻono).

ʻO ka ʻōnaehana Hepatobiliary. Hepatitis, hana aho ka hemahema.

ʻO nā maʻi o ka musculoskeletal, nā pilikia o ka hoʻopili ʻana a me nā iwi. ʻO Arthralgia, myalgia (i kekahi mau hihia i pili i ka piʻi nui o nā pae CPK serum), nā ʻōpū o ka naʻau.

Hōʻōnaehana hana ʻole a me ka ʻōnaehana urinary. Hoʻoulu i ka hana renal, a me ka hemahema paha i ka poʻe maʻi i ke koʻikoʻi (ʻike ʻia "ʻO nā hiʻohiʻona o ke hoʻohana").

Ma ka ʻāpana o ka ʻili a me ke kiko. Leukocytoclastic vasculitis.

Hoʻohana ma ka pediatrics. Ma kahi noi manuʻaka i ka wā he 3-ʻelua mau maka makapō i 318 mau keiki a me nā ʻōpio he 6 a 16 makahiki, me ka hypertension, ʻike ʻia nā hopena hope loa: ʻeha o ke poʻo (7.9%), hypotension (2.2%), mau ʻeha. (1.9%), uukuki (0.9%). I ka manawa o ka wiki he 26 mau pule e wehe ai, nā kuʻikahi mai ka maʻamau o nā ʻōnaehana o ka laboratori e nānā pinepine ʻia: he piʻi o ka hana (6.5%) a me ka hoʻonui ʻana iā CPK (SC) i ka 2% o nā keiki hoʻokipa.

Hoʻohana i ka wā hāpai a me ka lactation

Hoʻopili ʻia ka hoʻohana ʻana o ka lāʻau lapaʻau "Aprovel" i loko o ka II a me III nā trimesters o ka hapai. I ka lua a me ke kolu o ka mea i hoʻokō ʻia ai ka hapai, ʻo nā māka e hoʻopili pololei i ka ʻoihana renin-angiotensin hiki i ka hana ʻana i ka renal a i ka pēpē hou, hypoplasia o ka ulupepa o ka ʻōpiopio, a me ka make.

No ke kumu o ka akahele, ʻaʻole ia e ʻōlelo e hoʻohana ma ka trimester mua o ka hāpai ʻana.

Pono e hoʻololi i ka hoʻololiʻana i nā maʻi hou ma mua o ka hoʻohālikelike ʻia. Inā hoʻoholo ʻia ka hapai, hiki i ka hoʻohana mua ʻana o ka irbesartan ke hoʻopaʻa ʻia a hiki pono ke nānā pono ʻia ke ʻano o ka ʻōmaʻomaʻi a me ka hana ʻana o ka hana lawelawe ʻana me ka hoʻohana ʻana i ka ultrasound, inā e lōʻihi ka lōʻihi o ka mālama ʻana.

Hoʻopili ʻia ka hoʻohana ʻana o ka lāʻau "Aprovel" i ka wā o ka hoʻoulu ʻana. ʻAʻole i maopopo ka excreted o irbesartan ma ka umauma umauma. Hoʻopili ʻia ʻo Aprovel i ka waiū umauma i ka wā lactation.

Ua aʻo ʻia ʻo Aprovel ma ka heluna kanaka o nā keiki he 6 a 16 mau makahiki, akā ʻaʻole i lawa ka ʻike i kēia lā e hoʻonui i kona mau ʻike no ka hoʻohana ʻana i nā keiki a loaʻa mai nā ʻike hou.

Nā hiʻohiʻona noi

Hoʻolaha i BCC. ʻO ka hypotension arterial Symptomatic, ʻoiai ma hope o ka lawe ʻana i ka hana mua, hiki ke hōʻeha i nā mea maʻi me ka BCC haʻahaʻa a me / a me nā ʻano sodium haʻahaʻa ma muli o ke ʻano diuretic therapy, kaʻai me ka liʻiliʻi o ka paʻakai, ka ʻōpū ʻana, a me ka luaʻi. Pono e hoʻihoʻi ʻia kēia mau ʻōuli i ka maʻamau ma mua o ka hoʻohana ʻana i ka lāʻau "Aprovel."

Nā Hōʻōkiko Arterial. Ke hoʻohana nei i nā lāʻau lapaʻau e pili ana i ka renin-angiotensin-ald testosterone, he nui ka hopena o ka hoʻomohala ʻana i ka maʻi hypotension arterial a me ka hana ʻole ʻana i nā maʻi i nā maʻi me ka bilateral renal artery stenosis a i ka stenosis artery paha i ka lā hoʻokahi. ʻOiai ʻaʻole i ʻike ʻia nā hihia like me ka hoʻohana ʻana o ka lāʻau Aprovel, me ka hoʻohana ʻana o ka angiotensin I receptor antagonist, hiki ke loaʻa nā hopena like.

ʻO ka male ʻole a me ka hoʻololi ʻana i ka huehue. Ke hoʻohana nei iā Aprovel e mālama i nā mea maʻi me ka hana renal impaired, ʻo ia ka mea e mālama pono ai ka mālama pinepine ʻana i ka paʻakai serum a me nā pae creatinine. ʻAʻoheʻike i loaʻa me Aprovel no ka mālamaʻana i nā mea maʻi me nā maʻi luhi hou.

ʻO nā mea maʻi me ka hypertension arterial, maʻi maʻi o ka maʻi, a me ka maʻi II type. ʻAʻole ka like ka hopena o ka irbesartan ma luna o ka pēpē a me ka ʻōnaehana cardiovascular ma nā hui liʻiliʻi a pau i loiloi ʻia i kahi hōʻike o nā maʻi me ka maʻi puʻupuʻu koʻikoʻi. Ma keʻano kūikawā, ua lilo ia i mea kūpono i nā wahine a me nā kumuhana o ka lāhui keʻokeʻo.

Hyperkalemia E like me nā lāʻau ʻē aʻe e pili ana i ka renin-angiotensin-aldosterone, ulu ka hyperkalemia i ka wā o ka mālama ʻana me Aprovel, ka mea nui i ka hāʻule ʻana o ka renal, ʻo ka proteinuria koʻikoʻi ma muli o ka nephropathy maʻi a / a i ʻole hōʻeha puʻuwai. Manaʻo ʻia ka mālama ʻana i ka paʻa ʻana o ka potum serum i nā mea maʻi ma ka hopena.

Lithium. I ka manawa like, ʻaʻole i ʻōlelo ʻia ka lithium a me ka aprovel.

Stenosis o ka aortic a me mitral valve, obstructive hypertrophic cardiomyopathy. E like me nā vasodilator e pono ai, e hoʻohana i ka lāʻau lapaʻau me ka mālama nui loa i nā mea maʻi me ka aortic a mitral valen stenosis, obstructive hypertrophic cardiomyopathy.

Aldosteronism mua. ʻO ka mea maʻi me ka aldosteronism maʻamau ʻaʻole i pane aku i nā lāʻau antihypertensive e hana nei e ka pale ʻana i ka renin-angiotensin.No laila, ʻaʻole ʻōlelo ʻia ʻo Aprovel no ka mālama ʻana i nā mea maʻi.

Nā hiʻohiʻona maʻamau. I loko o nā mea maʻi me ka hana vascular a me ka hana renal e hilinaʻi nui loa i ka hana a renin-angiotensin-ald testosterone (no ka laʻana, i nā mea maʻi me ka puʻuwai naʻau nui ʻole a i lalo o ka maʻi o ke keiki, me ka stenosis renal arela), mālama ʻia me ka ACE inhibitors or the theiotensin-II receptor antagonists. ka mea e pili ana i kēia ʻōnaehana i hoʻopili me ka hypotension acute, azotemia, oliguria, a i kekahi manawa pilikia ʻole o ka kidney renal. E like me kekahi āpana antihypertensive, ʻo ka hoʻohaʻemi nui loa i ke kahe o ke koko i nā mea maʻi me ka ischemic cardiopathy a i ʻole ischemic cardiovascular disease hiki ke alakaʻi i myocardial infarction a i ʻole stroke. E like me nā mea paʻa o ka angiotensin-hoʻohuli o ka enzyme, irbesartan a me nā antagonika angiotensin e maopopo iki ʻole ka hopena o ka hoʻohaʻahaʻa ʻana i ke koko i nā ʻelele o ka lāhui ʻeleʻele ma mua o nā ʻelele o nā lāhui ʻē aʻe, malia paha no nā kūlana me ka haʻahaʻa haʻahaʻa o ka renin i ʻoi aku ka maʻamau ma waena o ka poʻe o nā poʻe maʻi o ka lāhui ʻeleʻele me ka hypertension . ^ E Ha yM.

Ua hoʻohālikelike ʻia ka hoʻohana ʻana i ka lāʻau lapaʻau no ka mālama ʻana i nā mea maʻi me nā pilikia hoʻoilina maʻamau - galactose intolerance, defapp Lapp lactase a i ʻole malabsorption glucose-galactose.

ʻO ka hiki ke alakaʻi i ka hopena i ka wā e lawe ana i nā kaʻa a i ʻole nā ​​hana ʻē aʻe

ʻO ka hopena i ka hiki ke alakaʻi i kahi kaʻa a hoʻokō i nā hana e koi ai i ka piʻi nui ʻana ʻaʻole i aʻo ʻia i aʻo ʻia. ʻO nā huahana pharmacokinetic o irbesartan e hōʻike nei he mea hiki ʻole ke hopena i kēia mākaukau.

Ke hoʻolele nei i kahi kaʻa a i ʻole ka hana me ka mīkini, pono e noʻonoʻo ʻia i ka luhi a me ka mauʻu hiki i ka wā o ka mālama ʻana.

ʻO nā waiwai Pharmacological

Lapaʻau lāʻau ʻO Aprovel kahi hanohano, ikaika paʻa, ʻonanopono aikawa neʻe neʻe me ke ʻano (type AT 1). Ua manaʻo ia ke kāohi i nā hopena koʻikoʻi a ka physiologically nui o ka angiotensin II i hoʻopili ʻia ma o ka ʻae ʻĀina AT 1, me ka mea o ke kumu a me ke ala o ka synthesis o ka angiotensin II. ʻO ka hopena koho antagonistic ma angiotensin II receptors (AT 1) alakaʻi i kahi hoʻonui i ka neʻe o ka renin a me ka angiotensin II i ka plasma a me kahi hoʻoluhi o ke kaohi o ke ald testosterone i loko o ka plasma. Ke hoʻohana ʻia i nā dosis i kauoha ʻia, ʻaʻole e loli nui ka pae o ka serum potassium. ʻAʻole ʻo Irbesartan e kāohi i ka ACE (kininase II) - he enzyme e hoʻoulu i ka angiotensin II, metabol metabol bradykinin i hana i ka metabolite hana ʻole. I mea e ʻike ai i kona hopena, ʻaʻole pono nā irbesartan e hoʻoikaika ai i ka metabola.

Ka hoʻokō maʻi i ka maʻi hypertension. Ua hōʻemi ʻo Aprovel i ke kahe o ke koko me ka loli liʻiliʻi o ka puʻuwai puʻuwai. Ka emi ʻana o ke koko i ka wā e lawe ai i ka manawa hoʻokahi i hilinaʻi ʻia i loko o ke ʻano, me ka leʻaleʻa e hōʻea i ka pā pulu i nā nui o ka 300 mg. ʻO nā helu o ka 150-300 mg ke kahe hoʻokahi i ka lā e hōʻemi i ke kahe koko i ke ana ma ka wahi a i ʻole e noho ana ma ka hopena o ka hana (ʻo ia hoʻi, 24 mau hola ma hope o ka lawe ʻana i ka lāʻau) ma ka awelika o 8-13 / 5-8 mm RT. ʻAniā. (systolic / diastolic) ʻoi aku ma mua o ka placebo.

ʻO ka emi loa o ke kahe koko e loaʻa ai nā hola 3-6 ma hope o ka lawe ʻana i ka lāʻau lapaʻau, hoʻomau ka hopena antihypertensive no 24 mau hola.

24 mau hola ma hope o ka lawe ʻana i nā kaila i manaʻo ʻia, ʻo ka emi ʻana o ke kahe o ke koko he 60-70% hoʻohālikelike ʻia me ka hōʻemi nui ʻana o ka pehu o diastolic a me systolic. ʻO ka lawe ʻana i ka lāʻau lapaʻau ma kahi hoʻokahi o 150 mg hoʻokahi i ka lā e hāʻawi i ka hopena (ma ka palena liʻiliʻi o ka hana a me ka awelika ʻo 24 mau hola), e like me ka mea i loaʻa i kēia helu ʻana i kēlā me kēia lā i nā maʻi ʻelua.

Hōʻike ʻia ka hopena antihypertensive o ka lāʻau "Aprovel" i loko o 1-2 mau pule, a ʻo ka hopena nui loa ka hopena i loaʻa i ka wiki he 4 mai ka hoʻomaka ʻana o ka mālama ʻana. Ke hoʻomau nei ka hopena antihypertensive me ka mālama lōʻihi. Ma hope o ka hoʻokuʻu ʻana i ka mālama ʻana, hoʻohaʻahaʻa ka lihihi o ke koko i kāna waiwai kumu. ʻO ka haʻaleleʻana o ka maʻi maʻi ma ke ʻano o ka piʻi o ka hypertension ma hope o ka haʻalele ʻana i ka lāʻau lapaʻau ʻaʻole i ʻike ʻia.

ʻO Aprovel me nā diuretics thiazide-type e hāʻawi i kahi hopena hypotensive hoʻohui. No ka poʻe maʻi i ka mea a irbesartan wale ʻole i hāʻawi i ka hopena i makemake ʻia, ka hoʻohana like ʻana o ka wai haʻahaʻa o ka hydrochlorothiazide (12.5 mg) me ka irbesartan hoʻokahi manawa o ka lā i hōʻemi ka nui o ke kahe koko i ka liʻiliʻi o 7-10 / 3-6 mm Hg. ʻAniā. (Systolic / diastolic) hoʻohālikelike me ka pletebo.

ʻAʻole hilinaʻi ka hopena o ka lāʻau "Aprovel" i nā makahiki a i ʻole ka wahine. ʻO nā mea maʻi o ka lāhui ʻeleʻele e loaʻa mai ana i ka hypertension ua loaʻa i ka pane haʻahaʻa loa i ka monotherapy me irbesartan, a me nā lāʻau ʻē aʻe e pili ana i ka ʻōnaehana renin-angiotensin. Ma ka hoʻohana pinepine ʻana o irbesartan me hydrochlorothiazide ma kahi haʻahaʻa (no ka laʻana, he 12.5 mg i kēlā me kēia lā), ʻo ka pane i ka poʻe maʻi o ka lāhui ʻeleʻele e hōʻea i ke kiʻekiʻe o ka pane i nā poʻe maʻi o ka lāhui keʻokeʻo. ʻAʻole i loli nui ka maʻi ma loko o ka nui o nā waikina serum uric a i ʻole urric acid excretion i nānā.

I nā keiki he 318 a me nā ʻōpio ʻo 6 a 16 mau makahiki i loaʻa he maʻi hypertension a i ʻole ka hopena o kona hōʻea (ʻo ka maʻi maʻi, ka hele ʻana o nā maʻi maʻi hypertensive ma ka ʻohana), ua aʻo ʻia nā hōʻemi o ke koko ma hope o nā ʻāpana o nā irbesartan - 0.5 mg / kg (haʻahaʻa). 1,5 mg / kg (awelika) a me 4.5 mg / kg (kiʻekiʻe) no ʻekolu pule. I ka hopena o ke kolu o ka wiki, ua hōʻemi ʻia ka liʻiliʻi o ke koko systolic koko ma ke kūlana noho (SATSP) mai ka pae mua ma ka awelika o 11.7 mm RT. ʻAniā. (Ka helu haʻahaʻa), 9.3 mmHg. ʻAniā. (Ka awelika helu), 13.2 mmHg. ʻAniā. (Hoka kiʻekiʻe). ʻAʻole i ʻike ʻia nā ʻokoʻa lahilahi nui ma waena o nā hopena o kēia mau hewa. ʻO ka hoʻololi hoʻololi maʻamau i hōʻemi iki ʻia i ke kao o ke koko (DATSP) i: 3.8 mmHg. ʻAniā. (Ka helu haʻahaʻa), 3.2 mmHg. ʻAniā. (Ka awelika helu), 5.6 mmHg. ʻAniā. (Hoka kiʻekiʻe). Ma hope oʻelua pule, ua hoʻopaʻa hou ʻia nā maʻi e hoʻohana i ka lāʻau lapaʻau a i ʻole placebo. I nā maʻi i loaʻa i ka placebo, ulu ʻo SATSP a me DATSP i ulu e 2.4 a me 2.0 mm Hg. Art., A i loko o ka mea i hoʻohana i ka irbesartan ma nā ʻano like ʻole, ʻo nā loli pili e pili ana he 0.1 a me -0.3 mm RT. ʻAniā.

Loaʻa ka ʻoihana maʻi maʻi ma nā maʻi me ka hypertension arterial, maʻi ʻeha, a me ke ʻano maʻi mellitus type II. Ke hōʻike nei ʻo IDNT (irbesartan no ka nephropathy maʻi) hōʻike i ka irbesartan e hoʻolohi ana i ka hoʻomōloana o ka hōʻeha o ka maʻi i ka poʻe maʻi me ka hana ʻole o ke aʻalolo a me ka proteinuria koʻikoʻi.

ʻO ka IDNT kahi ʻelua makapō, ka hoʻopaʻa i hoʻopaʻa ʻia e hoʻohālikelike i ka morbidity a me ka make ma waena o nā poʻe maʻi e loaʻa ana i nā aprovel, amlodipine, a me ka pletebo. Ua hui ʻia e nā maʻi 1715 me ka maʻi hypertension a me II diabetes mellitus, ka mea nona proteinuria ≥ 900 mg / lā a me ka pae serum bun ma ka pae o 1.0-3.0 mg / dl. ʻO nā hopena lōʻihi loa (ma ka awelika 2.6 mau makahiki) nā hopena o ka hoʻohana ʻana i ka lāʻau "Aprovel" i aʻo ʻia - ka hopena i ka hoʻomau ʻana o ka maʻi ʻōpiopio a me ka make holoʻokoʻa. Loaʻa nā mea maʻi i nā inikake titrated o 75 mg i 300 mg (mālama mālama ʻia) o Aprovel, 2,5 mg a 10 mg o ka amlodipine a i kahi pleta paha, ma muli o ka ʻoluʻolu. I kēlā me kēia hui, loaʻa i nā mea maʻi he mau lāʻau antihypertensive he 2-4 (e.g., diuretics, beta-blockers, alpha-blockers) e hoʻokō i kahi pahuhopu i koho mua ʻia - ke koko wailua ma ka pae o ≤ 135/85 mm Hg. ʻAniā. a i ʻole ka hoʻohemo ʻana i nā kaomi kahawai e 10 mm RT. Art., Inā ʻo ka pae mua loa ma> 160 mm RT. ʻAniā. Loaʻa ka pae ʻai koko o ka nui no ka 60% o nā maʻi i ka hui plasebo, a no 76% a me 78% i nā hui e loaʻa ana i ka irbesartan a me ka amlodipine, ma kēlā me kēia. Hoʻemi nuiʻo Irbesartan i ka hopena pili i kahi maka mua, i hui pū ʻia me ka pālua o ka serum creatinine, i ka hopena o ka maʻi hope, a i ʻole ka make. Ma kahi o 33% o nā mea maʻi e loaʻa i ka makaʻohui hui i hui mua ʻia i ka hui e like me 39% a me 41% i nā hui pletebo a me amlodipine; kahi hoʻohaʻahaʻa 20% i ka hopena pili i ka hoʻohālikelike ʻia (p = 0.024) a me ka hōʻemi he 23% i ka pili hoʻohālikelike ʻia me ka amlodipine (p = 0.006). I ka helu ʻia ʻana o nā ʻāpana ʻokoʻa o ka hopena o ka hopena, ka mea, ʻaʻohe hopena i ka make ma ke ʻano holoʻokoʻa, i ka manawa like, aia ke ʻano kūpono i ka hoʻēmi ʻana i nā hihia o ka hopena hope loa o ka maʻi ʻōnaʻi a me ka hoʻoliʻelika nui nui ma ka helu o nā hihia e ka papalua o ka serum creatinine.

ʻO ka loiloi o ka hopena hopena e lawe ʻia i nā kumupaʻa like ʻole, ka mea i kahele ʻia e ka wahine, ka lāhui, ka makahiki, ka lōʻihi o ka maʻi maʻi, kaomi mua o ke koko, ka hoʻokaʻawale ʻana o serum creatinine a me ka helu albumin excretion. Ma nā pūʻulu o nā wahine a me nā luna o ka lāhui ʻeleʻele, i helu ʻia no 32% a me 26% o ka heluna holoʻokoʻa noiʻi, kēlā, ʻaʻohe mea maikaʻi o ke kūlana o nā keiki, ʻoiai ʻaʻole i kaawale nā ​​manaʻo hilinaʻi. Inā mākou e kamaʻilio e pili ana i kahi hulina lua - he hanana cardiovascular i hoʻopau (ʻeha) a ʻaʻole i pau (nonfatal) make, a laila ʻaʻole like nā hōʻailona i waena o nā pūʻulu ʻekolu i ka heluna holoʻokoʻa, ʻoiai ka ulu o ka nonocatal myocardial infarction (MI) nui loa i loko o nā wahine a liʻiliʻi i nā kāne mai ka hui irbesartan i hoʻohālikelike ʻia me ka hui pletebo. Hoʻohālikelike ʻia me ka hui amlodipine, ʻoi aku ka nui o ka hanana o ka nonocardial infarction and stroke a ʻoi aku ka nui o nā wahine mai ka hui irbesartan, ʻoiai ka nui o nā hihia o ka haukapila no ka hoʻopiʻi ʻana i ka puʻuwai ma ka lehulehu holoʻokoʻa. ʻAʻohe ʻike kūʻiʻo i ke ʻano he hopena i loaʻa i ka wahine.

ʻO ka hōʻike "ʻo ka hopena o ka irbesartan ma microalbuminuria i nā maʻi me ka maʻi type mellitus type II a me hypertension" (IRMA 2) i hōʻike ʻia he 300 mg irbesartan i nā mea maʻi me ka microalbuminuria e hoʻomoe i ka holomua o ka hele ʻana o ka proteinuria maoli. ʻO IRMA 2 he makapō ʻelua, ʻike ʻia ka pleboebo i hoʻomalu ʻia i ka make ma waena o nā maʻi 590 me ka maʻi mellitus type II me ka microalbuminuria (30-300 mg i kēlā me kēia lā) a me ka hana renal maʻamau (serum creatinine ≤ 1.5 mg / dL i nā kāne a 300 mg i kēlā me kēia lā a me kahi hoʻonui o SHEAS ma ka liʻiliʻi o 30% o ka pae mua). He pahuhopu i koho mua ʻia ʻo ke koko ma ka pae o ≤135 / 85 mmHg. ʻAniā. No ke kōkua i ka hoʻokō ʻana i kēia pahuhopu, ua hoʻohui ʻia nā mea hoʻohui antihypertensive e like me ka mea e pono ai (koe wale nō naʻe no nā inhibitors ACE, angiotensin II receptor antagonists a me ka hānō neʻe dihydropyridine blockers). I nā hui lapaʻau āpau, like me ke kahe o ke koko i loaʻa i nā mea maʻi, akā i ka hui e loaʻa ana i ka 300 mg o irbesartan, nā hapa liʻiliʻi (5.2%) ma mua o ka poʻe e loaʻa ana i ka placebo (14.9%) a i 150 mg o irbesartan i kēlā me kēia lā (9.7%), hiki i ka hopena - wehewehe proturia. Hōʻike kēia i kahi hōʻemi 70% ma hope o ka pilikia ma hope o kahi hopena kiʻekiʻe e hoʻohālikelike ʻia me ka placebo (p = 0.0004). ʻO ka hoʻonui hoʻolōʻihi i ka helu filtration glomerular (GFR) i loko o nā mahina ʻekolu o ka mālama ʻana, ʻaʻole i mālama ʻia. ʻO ka hoʻolalelale ʻana i ka holomua o ka nānā ʻana o ka proteinuria i haʻi ʻia ma hope o ʻekolu mau mahina, a ua mau ʻia kēia hopena e ke kaʻaahi o kahi 2 mau makahiki. Ke kaumaha i ka normoalbuminuria (1 koho - nā helu

ʻO ka hiʻohiʻona o ka lāʻau lapaʻau

Hoʻokumu ʻia ka lāʻau lapaʻau i ka irbesartan. ʻO kēia kāna mea hana. ʻO nā mea ʻē aʻe aia i kēia papa, me ka:

1. Lāʻau Magnesium,
2. Silika
3. Lawaʻawa Lactose.

Ma mua o ka hoʻomaka ʻana i ka mālama ʻana, pono e heluhelu nā mea maʻi i ka kiʻina piha o ka lāʻau. He kūpono wale ia no kēlā poʻe i ʻole i kūpaʻa i kāna mau ʻāpana. Hiki i ke kauka ke kōkua i ke kuhikuhi i kēia, ʻo ia ka mea e noʻonoʻo nei i ke aʻo ʻana i ke kuhi ʻana o Aprovel hypertension.

E hoʻokuʻu i ke ʻano

ʻO ka lāʻau lapaʻau nā lālā o ka antagonist reseptor o ka lua o ka angiotensin. Ma ke kūʻai ʻia e ʻike ʻia ma ke ʻano pil. Ma ka lima ʻē aʻe, ʻike ʻia ke kākau ʻana ma luna o lākou. Hōʻike ʻo ia i nā naʻau. Ma ka ʻaoʻao hoʻohuli, ʻo ia ka helu 2872.

Aia he 2 mau wahi o ka lāʻau. ʻOkoʻa ka ʻokoʻa mai kēlā me kēia i kekahi i ka hana a nā mea hana ikaika. 150 mg o kēia mea ua loaʻa i loko o kekahi mau papa, a me 300 mg i kekahi. Mahalo i kēia, hoʻokele nā ​​kauka e koho i ka papa kūpono o ka lāʻau no ka mea maʻi, e kōkua iā ia e kū pū i ka maʻi, akā ʻaʻole e hoʻolauna i kahi hoʻopiʻi.

Hoʻonui ʻia ka lāʻau lapaʻau i nā ʻano like ʻole.

I ka wā hāpai a me ka lactation

Ua pāpā ʻia ʻo "Aprovel" 300 mg a me 150 mg no ka hoʻohana ʻana ma ka mālama ʻana i nā wahine hypertensive i loaʻa kahi keiki. Inā inu ka mea maʻi ma mua i kēia lāʻau lapaʻau, a laila pono e hoʻihoʻi ʻo ia iā ia ma hope o ka hāpai ʻana.

ʻAʻole hiki ke kapa ʻia ka hoʻohana ʻana i ka hopena i ka Aprovel no nā wahine e hoʻomaʻamaʻa ʻia. ʻO ka hōʻole ʻole ia e kōkua i ka pale ʻana i kā lākou keiki mai ka hoʻomohala ʻana i nā maʻi e hiki ai i ke ʻano ikaika o nā lāʻau lapaʻau ke alakaʻi.